JP2019528077A5 - - Google Patents

Download PDF

Info

Publication number
JP2019528077A5
JP2019528077A5 JP2019510951A JP2019510951A JP2019528077A5 JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5 JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019510951 A JP2019510951 A JP 2019510951A JP 2019528077 A5 JP2019528077 A5 JP 2019528077A5
Authority
JP
Japan
Prior art keywords
polypeptide
host cell
chimeric
antigen
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019510951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528077A (ja
JP7500195B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/048040 external-priority patent/WO2018039247A1/en
Publication of JP2019528077A publication Critical patent/JP2019528077A/ja
Publication of JP2019528077A5 publication Critical patent/JP2019528077A5/ja
Priority to JP2022057245A priority Critical patent/JP2022106714A/ja
Application granted granted Critical
Publication of JP7500195B2 publication Critical patent/JP7500195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019510951A 2016-08-23 2017-08-22 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法 Active JP7500195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022057245A JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378614P 2016-08-23 2016-08-23
US62/378,614 2016-08-23
PCT/US2017/048040 WO2018039247A1 (en) 2016-08-23 2017-08-22 Proteolytically cleavable chimeric polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022057245A Division JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2019528077A JP2019528077A (ja) 2019-10-10
JP2019528077A5 true JP2019528077A5 (enExample) 2020-09-24
JP7500195B2 JP7500195B2 (ja) 2024-06-17

Family

ID=61245300

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019510951A Active JP7500195B2 (ja) 2016-08-23 2017-08-22 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
JP2022057245A Ceased JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022057245A Ceased JP2022106714A (ja) 2016-08-23 2022-03-30 タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法

Country Status (9)

Country Link
US (3) US11401332B2 (enExample)
EP (1) EP3504245A4 (enExample)
JP (2) JP7500195B2 (enExample)
KR (2) KR102637610B1 (enExample)
CN (1) CN109843929B (enExample)
AU (1) AU2017316649A1 (enExample)
CA (1) CA3034093A1 (enExample)
SG (2) SG10201913583QA (enExample)
WO (1) WO2018039247A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
CN108367057B (zh) 2015-04-06 2022-11-22 赛通免疫股份有限公司 用于胶质母细胞瘤的egfr导向的car疗法
CN110225760B (zh) * 2016-09-15 2023-11-07 埃里西拉医疗公司 T细胞免疫疗法
MX2019003462A (es) * 2016-09-28 2019-08-16 Gavish Galilee Bio Appl Ltd Una plataforma universal para el tratamiento con car que se dirige a una novedosa firma antigenica del cancer.
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
US11807662B2 (en) * 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
KR20200131844A (ko) * 2018-03-16 2020-11-24 사이토이뮨 테라퓨틱스 인코퍼레이티드 이중특이적 항체 car 세포 면역요법
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
US20190307885A1 (en) 2018-04-04 2019-10-10 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3096200A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Trans-antigen targeting in heterogeneous cancers and methods of use thereof
EP3773633A4 (en) 2018-04-06 2022-01-26 The Regents of The University of California METHODS OF TREATMENT OF GLIOBLASTOMA
CA3096812A1 (en) * 2018-04-10 2019-10-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US12466892B2 (en) 2018-11-08 2025-11-11 The Regents Of The University Of California Systems and methods for targeting cancer cells
CA3121911A1 (en) * 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
US20220096547A1 (en) * 2019-01-03 2022-03-31 Nanjing Legend Biotech Co., Ltd. Modified immune cells expressing flagellin polypeptide
EP4010377A4 (en) * 2019-08-09 2023-09-06 A2 Biotherapeutics, Inc. CELL SURFACE RECEPTORS THAT RESPOND TO LOSS OF HETEROZYGOSIS
WO2021061862A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with hinge domain
WO2021061791A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
WO2021061859A1 (en) * 2019-09-24 2021-04-01 The Regents Of The University Of California Novel receptors for ligand-dependent transcriptional regulation
CN114728174A (zh) * 2019-09-24 2022-07-08 加利福尼亚大学董事会 具有异源跨膜结构域的受体
CN110716044B (zh) * 2019-10-23 2023-04-18 郑州大学 一种用于食管鳞癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法
US12195723B2 (en) 2019-11-08 2025-01-14 The Broad Institute, Inc. Engineered antigen presenting cells and uses thereof
CN110970090B (zh) * 2019-11-18 2021-06-29 华中科技大学 一种用于判断待处理多肽与阳性数据集肽段相似度的方法
CA3160614A1 (en) * 2019-12-12 2021-06-17 Marcela GUZMAN AYALA Method and compositions for regulated armoring of cells
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
US12459984B2 (en) 2019-12-27 2025-11-04 National University Corporation Kobe University Cancer gene therapy drug
WO2021207526A1 (en) * 2020-04-09 2021-10-14 The Regents Of The University Of California Humanized notch receptors with hinge domain
WO2021206910A1 (en) * 2020-04-09 2021-10-14 The Regents Of The University Of California Notch receptors with zinc finger-containing transcriptional effector
US20230226213A1 (en) * 2020-06-18 2023-07-20 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating cells and cellular membranes
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
EP4097486A4 (en) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING CEACAM POSITIVE CANCER
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
US20240150755A1 (en) * 2021-02-26 2024-05-09 Salk Institute For Biological Studies Modulating regulatory t cell function in autoimmune disease and cancer
CA3213044A1 (en) * 2021-03-23 2022-09-29 Kole T. ROYBAL Synthetic intermembrane proteolysis receptors for custom antigen-induced transcriptional regulation
CN114133440B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用
WO2022204326A1 (en) * 2021-03-24 2022-09-29 The Regents Of The University Of California Humanized synthetic notch receptors with augmented transactivation domains and uses thereof
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
CN114736308B (zh) * 2022-03-15 2022-12-27 四川宜美康科技有限公司 球虫抗原肽/il5的融合蛋白基因工程菌的制备及用途
CN117510615B (zh) * 2023-01-31 2025-01-07 上海恩凯细胞技术有限公司 SynNotch受体及其用途
CN122206449A (zh) * 2023-10-05 2026-06-12 加利福尼亚大学董事会 Card11-pik3r3融合蛋白的调节的表达

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780300A (en) 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
GB0112818D0 (en) * 2001-05-25 2001-07-18 Lorantis Ltd Conjugate
GB0220658D0 (en) 2002-09-05 2002-10-16 Lorantis Ltd Immunotherapy
HRP20160082T1 (hr) * 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
EP2195658A2 (en) 2007-09-28 2010-06-16 Royal College of Surgeons in Ireland A method of assessing colorectal cancer status in an individual
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
WO2011130624A2 (en) 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
GB201306536D0 (en) * 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US20160250258A1 (en) 2013-10-31 2016-09-01 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
US9730935B2 (en) 2013-12-13 2017-08-15 The Board Of Trustees Of The Leland Stanford Junior University Targeting a non-canonical notch signaling pathway for cancer treatment
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
JP6665102B2 (ja) 2014-02-21 2020-03-13 セレクティスCellectis 制御性t細胞をインサイチューで阻害するための方法
WO2015130766A1 (en) * 2014-02-25 2015-09-03 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
WO2016019300A1 (en) * 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
DK3186284T3 (da) 2014-08-28 2022-05-09 Bioatla Inc Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
KR20170095284A (ko) * 2014-12-09 2017-08-22 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 종양 항원 펩티드
EP3262166A4 (en) 2015-02-24 2018-08-15 The Regents of The University of California Binding-triggered transcriptional switches and methods of use thereof
WO2017193059A1 (en) 2016-05-06 2017-11-09 The Regents Of The University Of California Systems and methods for targeting cancer cells

Similar Documents

Publication Publication Date Title
US12030953B2 (en) Chimeric antigen receptors, compositions, and methods
JP2020503885A5 (enExample)
JP6784687B2 (ja) 結合誘発型転写スイッチ及びその使用方法
JP2019519227A5 (enExample)
JP2018519296A5 (enExample)
JP2023506452A5 (enExample)
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
IL275743A (en) New bispecific format suitable for use in high-through-put screening
JP2021525530A5 (enExample)
JP2019514361A5 (enExample)
JP2020512820A5 (enExample)
JP2017518037A5 (enExample)
JP2017522891A5 (enExample)
JP2018528786A5 (enExample)
JP2019521643A5 (enExample)
JP2024023228A5 (enExample)
JP2017506882A5 (enExample)
JP2018529327A5 (enExample)
JP2022513116A5 (enExample)
RU2019134273A (ru) Конструкты индуктора презентации антигена опухоли и их использование
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2015528003A5 (enExample)
JP2017501702A5 (enExample)
JP2019530440A5 (enExample)
CN111448214A (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用